These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38566448)

  • 1. A review on comprehending immunotherapeutic approaches inducing ferroptosis: Managing tumour immunity.
    Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S
    Immunology; 2024 Aug; 172(4):547-565. PubMed ID: 38566448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Newcastle disease virus induced degradation of YAP through E3 ubiquitin ligase PRKN to exacerbate ferroptosis in tumor cells.
    Sun Y; Tang L; Kan X; Tan L; Song C; Qiu X; Liao Y; Nair V; Ding C; Liu X; Sun Y
    J Virol; 2024 Mar; 98(3):e0189723. PubMed ID: 38411946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
    Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
    EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arming oncolytic viruses to leverage antitumor immunity.
    de Gruijl TD; Janssen AB; van Beusechem VW
    Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newcastle-disease-virus-induced ferroptosis through nutrient deprivation and ferritinophagy in tumor cells.
    Kan X; Yin Y; Song C; Tan L; Qiu X; Liao Y; Liu W; Meng S; Sun Y; Ding C
    iScience; 2021 Aug; 24(8):102837. PubMed ID: 34368653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic cell death-based oncolytic virus therapy: A sharp sword of tumor immunotherapy.
    Zhang J; Chen J; Lin K
    Eur J Pharmacol; 2024 Oct; 981():176913. PubMed ID: 39154830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune landscape and response to oncolytic virus-based immunotherapy.
    Lin C; Teng W; Tian Y; Li S; Xia N; Huang C
    Front Med; 2024 Jun; 18(3):411-429. PubMed ID: 38453818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newcastle disease virus: a promising agent for tumour immunotherapy.
    Zhao L; Liu H
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Viruses: Therapeutics With an Identity Crisis.
    Breitbach CJ; Lichty BD; Bell JC
    EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
    Meng Q; He J; Zhong L; Zhao Y
    Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
    Hofman L; Lawler SE; Lamfers MLM
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells.
    Soroush A; Shahhosseini R; Ghavamikia N; Hjazi A; Roudaki S; KhalatbariLimaki M; Mirbolouk M; Pakmehr S; Karimi P
    Cell Biochem Funct; 2024 Jun; 42(4):e4055. PubMed ID: 38856033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8
    Wang W; Green M; Choi JE; Gijón M; Kennedy PD; Johnson JK; Liao P; Lang X; Kryczek I; Sell A; Xia H; Zhou J; Li G; Li J; Li W; Wei S; Vatan L; Zhang H; Szeliga W; Gu W; Liu R; Lawrence TS; Lamb C; Tanno Y; Cieslik M; Stone E; Georgiou G; Chan TA; Chinnaiyan A; Zou W
    Nature; 2019 May; 569(7755):270-274. PubMed ID: 31043744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of NK cells in immunotherapy and virotherapy of solid tumors.
    Cantoni C; Grauwet K; Pietra G; Parodi M; Mingari MC; De Maria A; Favoreel H; Vitale M
    Immunotherapy; 2015; 7(8):861-82. PubMed ID: 26314197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.